Core Viewpoint - Clearmind Medicine Inc. has announced the publication of a patent for its innovative combination therapy of MEAI and N-Acylethanolamines aimed at treating cocaine addiction, marking a significant advancement in the field of psychedelic-derived therapeutics [1][4]. Group 1: Patent and Research Developments - The patent was published by the Korean Intellectual Property Office and is based on preclinical trial results from Bar-Ilan University, showing that MEAI significantly reduces cocaine-induced cravings in animal models [1][2]. - Further studies indicated that MEAI's effects on drug-seeking behavior do not impair responses to natural rewards, suggesting a targeted approach to drug-related compulsions rather than a general impact on the reward system [3]. Group 2: Collaboration and Intellectual Property - Clearmind is collaborating with SciSparc Ltd. to combine MEAI with SciSparc's PEA, enhancing the development of therapies for addiction and mental health disorders [4]. - The company's intellectual property portfolio includes nineteen patent families with 31 granted patents, and it plans to pursue additional patents to strengthen its position in the market [6].
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea